Introducing 'Health Vulnerability'. Towards a Human Right Claim for Innovative Orphan Drugs? [0.03%]
“健康脆弱性”的提出？创新孤儿药的人权诉求吗？
Éloïse Gennet
Éloïse Gennet
Although several European law instruments specifically promote the development of orphan medicines, rare disease patients still suffer from an excessive lack of access to orphan drugs. In order to base a claim for equity of access to resear...
André den Exter
André den Exter
New treatment options for various cancer therapies appear to be extremely expensive and prices may increase further. The affordability and availability of life-saving medicines is therefore a key issue in the national health policies of all...
Verena Stühlinger
Verena Stühlinger
For patients, innovations in healthcare can be both a great blessing (when saving people's life or improving quality of life), as well as a curse (when only few people have access, e.g., because of high prices). Thus, when healthcare innova...
European Court of Justice [0.03%]
欧洲法院
An Baeyens
An Baeyens
In dubio pro CPR? The Controversial Status of 'Do Not Resuscitate' Imprints on the Human Body - a Swiss Innovation [0.03%]
未知偏好复苏？烙印在人体上的“不复苏”指令——一种瑞士创新之举？
Melanie Levy
Melanie Levy
'Do not resuscitate' (DNR) imprints on the human body have recently appeared in medical practice. These non-standard DNR orders (e.g., tattoos, stamps, patches) convey the patient's refusal of resuscitation efforts should he be incapable of...
Ethical, Legal and Regulatory Issues of Paediatric Translational Research. Call for an Adequate Model of Governance [0.03%]
儿科转化研究的伦理、法律和监管问题。呼吁建立适当的治理模式
Annagrazia Altavilla,Viviana Giannuzzi,Mariangela Lupo et al.
Annagrazia Altavilla et al.
The lack of paediatric medicines, including innovative and advanced ones, is a long-lasting and well-known problem at European and international levels. Despite the existing legal frameworks and incentives, children remain deprived of many ...
Introducing Key Elements Regarding Access to Personal Data for Scientific Research in the Perspective of Developing Innovative Medicines [0.03%]
从研发创新药物的角度论科学界获取个人数据的关键要素
Jean Herveg,Annagrazia Altavilla
Jean Herveg
This article aims at opening discussions and promoting future research about key elements that should be taken into account when considering new ways to organise access to personal data for scientific research in the perspective of developi...
High Price Medicines and Health Budgets: The Role Patients' and Consumers' Organisations Can Play [0.03%]
高价药物与卫生预算：患者和消费者组织可以发挥什么作用？
François Houÿez
François Houÿez
Healthcare systems face challenges due to budget constraints, complex therapies, and new treatments for rare diseases. One of the most successful patient advocacy campaigns of all times was initiated by people living with HIV and AIDS in Af...
Fedele Bonifazi,Elisabetta Volpe,Giuseppe Digregorio et al.
Fedele Bonifazi et al.
The use of machine learning (ML) in medicine is becoming increasingly fundamental to analyse complex problems by discovering associations among different types of information and to generate knowledge for medical decision support. Many regu...
Exploring Solutions to Foster ATMP Development and Access to Patients in Europe [0.03%]
探索在欧洲促进先进治疗药物发展及患者获取的解决方案
Vincenzo Salvatore
Vincenzo Salvatore
There are several critical factors that have influenced the (un)success rate of advanced therapy medicinal products (ATMPs) over the first ten years since the EU Regulation 1394/2007 entered into force. This article provides an overview of ...